Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%.

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025. With a disciplined grip on costs and a keen eye on margin growth, Pfizer’s ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Josh Brown, CEO of Ritholtz Wealth Management, explained in a recent program on CNBC why he’s bearish on Pfizer. Brown said he was “dead wrong” in hoping to see a turnaround at the pharma giant.

Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (PFE 0.06%) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in ...

Just how big Pfizer will be is hard to say. There's a lot of negativity about the company's prospects baked into its share price, with the stock trading at only 8.3 times forward earnings.

Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ...